Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
Hirokazu Takahashi, Keizo Anzai – 8 May 2022
Hirokazu Takahashi, Keizo Anzai – 8 May 2022
Emily Truong, Yee Hui Yeo, Galen Cook‐Wiens, Mark Muthiah, Ju Dong Yang, Vinay Sundaram, Devon Chang, Tsuyoshi Todo, Irene K. Kim, Shelly C. Lu, Veronica Wendy Setiawan, Vincent W. S. Wong, Stephen A. Harrison, Naim Alkhouri, Mazen Noureddin – 8 May 2022 – Studies have examined nonalcoholic fatty liver disease (NAFLD) prevalence and severity in Asians; however, this is not well understood in Asian Americans (both East and South Asian Americans) as few studies have analyzed this population.
Cyriac Abby Philips, Ajay Kumar Patwa, Pavan Hanchanale, Chetan Kalal, Saptarshi Bishnu, Mithun Sharma, the Liver Research Club India (LIVERECI) – 8 May 2022
Ammar Hassan, Pratima Sharma – 8 May 2022
Ammar Hassan, Pratima Sharma – 8 May 2022
Surender Singh, Nikhil Bush, Sunil Taneja – 8 May 2022
Yasser Fouad, Waleed A. Abdel Dayem, May Mehrez – 8 May 2022
Alexander H. Yang, Mai Ai Thanda Han, Niharika Samala, Bisharah S. Rizvi, Rachel Marchalik, Ohad Etzion, Elizabeth C. Wright, Ruchi Patel, Vinshi Khan, Devika Kapuria, Vikramaditya Samala Venkat, David E. Kleiner, Christopher Koh, Jennifer A. Kanakry, Christopher G. Kanakry, Steven Pavletic, Kirsten M. Williams, Theo Heller – 8 May 2022 – Hepatic graft‐versus‐host disease (HGVHD) contributes significantly to morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Clinical findings and liver biomarkers are neither sensitive nor specific.
Linda Henry, James M. Paik, Zobair M. Younossi – 8 May 2022